Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitatio...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2019-06, Vol.80 (4), p.404-424
Main Authors: Narmani, Asghar, Rezvani, Melina, Farhood, Bagher, Darkhor, Parvaneh, Mohammadnejad, Javad, Amini, Bahram, Refahi, Soheila, Abdi Goushbolagh, Nouraddin
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
Bioavailability
Biodegradability
Biodegradation
Cancer
cancer diagnosis and therapy
Cancer therapies
Cell Line, Tumor
Chemical compounds
Chemotherapy
Clinical trials
Conjugation
Drug Carriers - chemistry
Drug delivery
Drug Delivery Systems
Drug Evaluation, Preclinical
Folic acid
Folic Acid - chemistry
Glycoproteins
Humans
Medical research
Nanoparticles
Nanoparticles - chemistry
nanotechnology
Neoplasms - drug therapy
Neoplasms - pathology
Permeability
Pharmacology
Radiation therapy
Surgery
targeted drug delivery
Vitamin B
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from P‐glycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed‐folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR‐mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs‐based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented.
ISSN:0272-4391
1098-2299
DOI:10.1002/ddr.21545